https://www.selleckchem.com/pr....oducts/cid755673.htm
mutation and rearrangement was revealed by next-generation sequencing (NGS), and the targeted therapy, olaparib, was given. Efficacy evaluation showed SD for 1 year, and no obvious toxic and side effects were observed. Our case suggested that NGS should be considered for further treatment of patients with colorectal LMS, and poly (ADP-ribose) polymerase (PARP) inhibitors could be a feasible therapy for LMS patients with alterations. Our case suggested that NGS should be considered for further treatment of patients with colorectal LMS,
Like
Comment
Share
